OBJECTIVE: The purpose of this study was to assess the urogenital effects of @entity441 , @entity440 , conjugated @entity1641 @entity172 , and placebo in healthy postmenopausal @entity1 . STUDY DESIGN: This randomized, double-blind, placebo-controlled study compared the urogenital effects of 0.625 mg of conjugated @entity1641 @entity172 (n = 15 @entity1 ), 20 mg of @entity440 (n = 14 @entity1 ), 60 mg of @entity441 , (n = 15 @entity1 ), and placebo (n = 13 @entity1 ). Evaluations at baseline and evaluations after 20 weeks receiving the drug included a pelvic examination with cytologic evaluation of @entity8376 , pelvic organ prolapse quantitation, and urethral @entity2270 by @entity2708 swab test (only in @entity1 with @entity322 [33%]). RESULTS: Conjugated @entity1641 @entity172 increased the maturation value of both urethral and vaginal cytologic condition (P =.002, P =.032, respectively). There was a decrease in vaginal maturation value in the @entity441 group (not significant). Two of 8 @entity1 in the conjugated @entity1641 @entity172 group showed evidence of worsening prolapse by pelvic organ prolapse quantitation; the condition of 2 of 8 @entity1 improved. In the @entity441 , @entity440 , and placebo groups 8 of 12 @entity1 , 4 of 13 @entity1 , and 2 of 11 @entity1 had worsening in prolapse scores, respectively, whereas none of the @entity1 had improvement. Increased @entity2708 swab deflection was found in 3 of 5 @entity1 in the @entity441 group, in 5 of 8 @entity1 in the @entity440 group, in 0 of 4 @entity1 in the placebo group, and in 0 of 2 @entity1 in the conjugated @entity1641 @entity172 group. Seventy-five percent of the @entity1 who received @entity441 and 60% of the @entity1 who received @entity440 had increases in prolapse by any measure (ie, pelvic organ prolapse quantitation or @entity2708 swab or clinical assessment) compared with 18% of the @entity1 in the placebo group and 22% of the @entity1 in the conjugated @entity1641 @entity172 group (P =.015), although symptoms did not differ among groups. CONCLUSION: Neither @entity441 nor @entity440 improve cytohormonal effects in the vagina or urethra, whereas conjugated @entity1641 @entity172 does. @entity441 and @entity440 appear to show worsening prolapse compared with conjugated @entity1641 @entity172 and placebo. The clinical relevance of these effects is unknown and requires investigation.

Short-term urogenital effects of XXXX , @entity440 , and @entity172 .

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity1641 :: ('9796', 'Species') :: ['equine'] @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity2708 :: ('3635', 'Species') :: ['cotton'] @entity8376 :: ('MESH:D014625', 'Disease') :: ['vagina and urethra'] @entity2270 :: ('MESH:C566610', 'Disease') :: ['axis deflection'] @entity441 :: ('MESH:D020849', 'Chemical') :: ['raloxifene', 'Raloxifene']
@entity441 :: (MESH:D020849,Chemical) :: ['raloxifene']
